Related Experiment Video

Updated: Feb 16, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan

Ioannis Karydis1,2, Alexandra Gangi3, Matthew J Wheater2

  • 1Cancer Sciences Academic Unit, University of Southampton, Southampton, United Kingdom.

Journal of Surgical Oncology
|December 29, 2017
PubMed
Abstract

Insights

Melphalan percutaneous hepatic perfusion (M-PHP) offers durable intrahepatic disease control for metastatic uveal melanoma patients. This treatment shows promising survival outcomes and can be a foundation for multimodal therapy.

Area of Science:

  • Oncology
  • Hepatology
  • Interventional Radiology

Background:

  • Metastatic uveal melanoma (UM) has a poor prognosis with frequent liver recurrence.
  • Current systemic treatments offer limited efficacy for UM.
  • Melphalan percutaneous hepatic perfusion (M-PHP) enables targeted high-dose chemotherapy delivery to the liver.

Purpose of the Study:

  • To evaluate the outcomes of M-PHP in patients with metastatic uveal melanoma.
  • To assess tumor response, survival, and toxicity associated with M-PHP treatment.

Main Methods:

  • Retrospective analysis of outcomes data from 51 UM patients treated with M-PHP at two institutions.
  • Tumor response assessed using RECIST 1.1 criteria.
  • Toxicity evaluated per Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

Main Results:

  • 49% of patients achieved partial or complete hepatic response; 82.4% had hepatic disease control.
  • Median overall progression-free survival was 8.1 months, hepatic progression-free survival was 9.1 months.
  • Median overall survival was 15.3 months with no treatment-related fatalities. Grade 3-4 non-hematologic events occurred in 37.5% of patients.

Conclusions:

  • M-PHP achieves durable intrahepatic disease control in UM patients.
  • M-PHP can be integrated into multimodal treatment strategies for selected UM patients.
  • This approach offers a viable option for managing liver metastases in UM.
Keywords:
chemosaturationintrahepatic percutaneous haemoperfusionliver metastasismelphalanunresectable liver tumoruveal melanoma

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.4K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

997

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
282
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
256
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
987
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
211